Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.77 |
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | NT5E | P21589 | 1/20 | 0.52 |
| ▸ | BRAF | P15056 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | CDC7 | O00311 | 2/20 | 0.51 |
| ▸ | DBF4 | Q9UBU7 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29783018 | 1.00 | CYP3A4 (0.77) | CYP3A4CYP1A2CYP2C19LMNAKMT2A | |
| Hydrochloric Acid SCHEMBL1679765 | 0.99 | CYP3A4 (0.75) | CYP3A4CYP1A2CYP2C19LMNAKMT2A | |
| SCHEMBL289321 | 0.89 | CYP3A4 (0.62) | CYP3A4CYP1A2CYP2C19LMNAKMT2A | |
| SCHEMBL11387955 | 0.89 | CYP1A2 (0.73) | CYP3A4CYP1A2CYP2C19LMNAKMT2A | |
| SCHEMBL595294 | 0.88 | CYP1A2 (0.77) | CYP3A4CYP1A2CYP2C19LMNAKMT2A | |
| Hydrochloric Acid SCHEMBL289747 | 0.88 | CYP3A4 (0.61) | CYP3A4CYP1A2CYP2C19LMNAKMT2A | |
| SCHEMBL5211666 | 0.87 | CYP1A2 (1.00) | CYP3A4CYP1A2CYP2C19LMNAKMT2A | |
| Hydrochloric Acid SCHEMBL11388179 | 0.87 | CYP1A2 (0.75) | CYP3A4CYP1A2CYP2C19LMNAKMT2A | |
| SCHEMBL3065347 | 0.87 | CYP1A2 (0.75) | CYP3A4CYP1A2CYP2C19LMNAKMT2A | |
| Hydrochloric Acid SCHEMBL11388173 | 0.86 | CYP1A2 (0.73) | CYP3A4CYP1A2CYP2C19LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114990587-B | Electrochemical synthesis method of thiazole compound | 华南理工大学 | 2023-05-23 | — | — | CN | disclosed |
| CN-114990587-A | Electrochemical synthesis method of thiazole compound | 华南理工大学 | 2022-09-02 | — | — | CN | disclosed |
| EP-3954681-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | Bristol-Myers Squibb Company (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3402790-B1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2021-10-06 | — | — | EP | disclosed |
| US-9451775-B2 | Heterocyclic compounds as pesticides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-09-27 | — | — | US | disclosed |
| US-9451775-B2 | Heterocyclic compounds as pesticides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-09-27 | — | — | US | disclosed |
| US-9451775-B2 | Heterocyclic compounds as pesticides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-09-27 | — | — | US | disclosed |
| EP-2583556-B1 | Heterocyclic compounds as pest controllers | BAYER CROPSCIENCE AG (DE) | 2016-01-20 | — | — | EP | disclosed |
| EP-2583556-B1 | Heterocyclic compounds as pest controllers | BAYER CROPSCIENCE AG (DE) | 2016-01-20 | — | — | EP | disclosed |
| EP-2591674-B1 | Heterocyclic compounds as pest controllers | BAYER CROPSCIENCE AG (DE) | 2016-01-13 | — | — | EP | disclosed |
| EP-1581231-A1 | ANTI-VIRAL COMPOUNDS | Cyclacel Limited (GB) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004043467-A1 | ANTI-VIRAL COMPOUNDS | CYCLACEL LIMITED (GB) | 2004-05-27 | — | — | WO | disclosed |
| US-6699854-B2 | 2-SUBSTITUTED 4-HETEROARYL- PYRIMIDINES, INHIBITORS OF CYCLIN-DEPENDENT KINASES (CDKS) | CYCLACEL LIMITED (GB) | 2004-03-02 | — | — | US | disclosed |
| US-20030149057-A1 | Anti-cancer compounds | CYCLACEL LIMITED (GB) | 2003-08-07 | — | — | US | disclosed |
| CN-1420884-A | 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative diseases | CYCLACEL LTD (GB) | 2003-05-28 | — | — | CN | disclosed |
| US-6531479-B2 | Anticancer agents, skin disorders | CYCLACEL LIMITED (GB) | 2003-03-11 | — | — | US | disclosed |
| EP-1274705-A1 | 2-SUBSTITUTED 4-HETEROARYL-PYRIMIDINES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | Cyclacel Limited (GB) | 2003-01-15 | — | — | EP | disclosed |
| US-20020019404-A1 | Anti-cancer compounds | CYCLACEL LIMITED (GB) | 2002-02-14 | — | — | US | disclosed |
| WO-2001072745-A1 | 2-SUBSTITUTED 4-HETEROARYL-PYRIMIDINES AND THEIR USE IN THE TREATMETN OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2001-10-04 | — | — | WO | disclosed |
| US-4080457-A | INSECTICIDES, PESTICIDES, MITICIDES | UNIROYAL CHEMICAL COMPANY, INC. | 1978-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019404-A1 | Anti-cancer compounds | CDK3, CDK2, CDK4 | CYP3A4 2674/4885CYP1A2 2580/4885CYP2C19 2882/4885 |
| US-20030149057-A1 | Anti-cancer compounds | CDK3, CDK2, CDK4 | CYP3A4 2674/4885CYP1A2 2580/4885CYP2C19 2882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.